Biosimilar Antibodies

Muzastotug is a humanized immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). It functions as both an immunostimulant and an antineoplastic agent. This antibody is designed to enhance the immune system's response against tumor cells by inhibiting CTLA-4, a protein that downregulates the immune response.

Trinbelimab, designated as r-anti-D, is a monoclonal antibody specifically engineered for biochemical research applications. This antibody targets and binds to specific antigens, facilitating a wide range of studies in cellular and molecular biology. Trinbelimab's precision in antigen recognition makes it a valuable tool for researchers investigating cellular processes, immune responses, or disease mechanisms.

Pembrolizumab is a humanized IgG4 monoclonal antibody that functions as a programmed death-1 (PD-1) inhibitor. It effectively blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This inhibition prevents the suppression of T-cell activity, typically mediated by PD-1 signaling in cells expressing these ligands, thereby enhancing the immune response against tumor cells. Pembrolizumab is utilized extensively in immunotherapy protocols for various cancers, leveraging its ability to modulate immune system responses.

Pexelizumab (h5G1.1-SC) is a humanized single-chain variable fragment (scFv) monoclonal antibody that specifically targets the C5 component of the complement system. This antibody effectively inhibits key processes such as apoptosis and leukocyte infiltration, thereby modulating inflammatory responses. It is primarily utilized in research focused on cerebral ischemia-reperfusion (IR) injury and myocardial infarction, providing a valuable tool for investigating the role of the complement system in these conditions.

Ragifilimab (INCAGN-1876) is an agonistic monoclonal antibody designed to specifically target the glucocorticoid-induced TNFR-related protein (GITR). This antibody has been developed for use in research involving advanced or metastatic solid tumors, exploring its potential to modulate immune responses and enhance anti-tumor activity. Ragifilimab provides a valuable tool for investigating the therapeutic implications of GITR activation in oncological studies.

Duvortuxizumab (MGD 011) is a chimeric, humanized immunoglobulin antibody designed for dual targeting of CD19 and CD3E. This bifunctional antibody facilitates the engagement of T cells and B cells, promoting immune-mediated clearance of CD19-expressing cells. It is primarily utilized in research focused on the therapeutic potential in B-cell malignancies and other hematologic disorders.

Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Amyloid Beta (Aβ) peptides. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Anti-Amyloid Beta Antibody (CNTO 2125) is essential for research focusing on Alzheimer's disease and other amyloid-related disorders, providing a crucial tool for the detection and quantification of Amyloid Beta peptides.

GSK-3174998 is a humanized IgG1 monoclonal antibody that functions as an agonist to OX40 (TNFRSF4), a member of the TNF receptor superfamily. This antibody is designed to selectively bind to OX40, enhancing the immune response against cancer cells. It holds significant potential for research into the treatment of advanced solid tumors. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-CD25/IL-2Rα Antibody (7G7B6) is a chimeric monoclonal antibody derived from mouse IgG2a, specifically designed to target human CD25/IL-2Rα. This antibody is ideal for investigating the role of CD25/IL-2Rα in immune regulation and has applications in various immunological assays. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as the isotype control.

Abazistobart is a chimeric and humanized monoclonal antibody designed to act as both an immunostimulant and an antineoplastic agent. It specifically targets the programmed cell death protein 1 (PDCD1), effectively blocking its signaling pathway. This blockade results in the activation of the immune system and exhibits antineoplastic activity, making Abazistobart a valuable tool in cancer research.

Acapatamab (AMG-160) is a monoclonal antibody designed to target both CD3E and FOLH1. This dual-targeting biologic is engineered for the potential treatment of various cancers, leveraging its ability to bind to CD3E on T cells and FOLH1 on tumor cells, thereby facilitating a targeted immune response against cancerous tissues. Acapatamab is primarily used in research focused on cancer immunotherapy and the study of bispecific antibody mechanisms.

Opucolimab is a recombinant human monoclonal antibody targeting PD-L1 (Programmed Death-Ligand 1). This antibody is specifically designed for the development of antibody-drug conjugates. Opucolimab is primarily utilized in research focused on the treatment of advanced solid tumors, providing a critical tool for investigations into cancer immunotherapy.

The Anti-c-Kit/CD117 Antibody (SR-1) is a chimeric mouse monoclonal antibody of the IgG2a, κ subclass, designed to specifically target human c-Kit/CD117. This antibody is ideal for research focused on the biology and pathology of c-Kit/CD117-expressing cells. For accurate experimental control, it is recommended to use Mouse IgG2a kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.

AV-380 is a humanized IgG1 monoclonal antibody that specifically targets Growth Differentiation Factor 15 (GDF15). This antibody is designed for high specificity and affinity in binding to GDF15, making it an essential tool for research focused on understanding the role of GDF15 in various physiological and pathological processes. AV-380 is suitable for a range of experimental applications, including but not limited to, flow cytometry, Western blotting, and immunohistochemistry.

SAIT-301 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the hepatocyte growth factor receptor (HGFR), also known as c-Met. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-CXCL12/SDF1a Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL12/SDF1a. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, reference is made to the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons. This product is essential for research focusing on the biological pathways and interactions involving CXCL12/SDF1a, which are critical in immunological signaling and cellular migration processes.

Anti-CEACAM5 Antibody (4H11-8) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CEACAM5. For optimal experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the isotype control for this antibody.

LY3022859 (IMC-TR1) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TGFβR2. This antibody is comprised of a human IgG1 type heavy chain and a human κ-type light chain, with a predicted molecular weight of 143 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Upanovimab (SCTA01) is a monoclonal antibody specifically designed to target the spike (S) protein of SARS-CoV-2. This antibody binds with high specificity and affinity to the S protein, potentially neutralizing the virus and preventing its entry into host cells. Upanovimab is utilized in research focused on the therapeutic and prophylactic potential against COVID-19.

Bleselumab (ASKP 1240) is a humanized monoclonal antibody targeting CD40 with a high affinity of approximately 0.24 nM. By selectively binding to CD40, Bleselumab effectively blocks the interaction between CD40 and its ligand CD40L, a crucial pathway in immune response modulation. This inhibition is particularly relevant in preventing organ transplant rejection, making Bleselumab a significant tool in transplant immunology research.

Anetumab is a monoclonal antibody specifically targeting mesothelin (MSLN), a well-recognized tumor-associated antigen prevalent in various malignant tumors. This antibody serves as a foundational component in the synthesis of Anetumab ravtansine, an antibody-drug conjugate (ADC) that selectively delivers cytotoxic agents to MSLN-expressing tumor cells. Anetumab is primarily utilized in research settings to investigate the therapeutic potential and targeting efficacy against mesothelin-positive malignancies.

Erenumab is a fully human monoclonal antibody designed to selectively target and inhibit the calcitonin gene-related peptide (CGRP) receptor. This inhibition is crucial for the prevention of episodic migraine, as it interferes with the pathway believed to play a key role in the initiation of migraine episodes. Erenumab is specifically developed for prophylactic applications, offering a therapeutic approach for patients suffering from frequent migraine attacks.

Lorvotuzumab is a humanized monoclonal antibody that specifically targets CD56 (NCAM1), a surface molecule widely expressed in various neural and muscle tissues, and certain types of cancer cells. This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), including the synthesis of Lorvotuzumab mertansine, an ADC designed for targeted cancer therapy. Lorvotuzumab's high specificity and binding affinity make it an essential tool in research focused on the therapeutic targeting of CD56-expressing cells.

Tesidolumab (LFG316) is a fully human IgG1/λ monoclonal antibody with a molecular weight of 143 kDa in its non-glycosylated form. This antibody specifically targets and binds to complement component 5 (C5), effectively inhibiting its cleavage and the subsequent formation of the membrane attack complex (MAC). This blockade is crucial in preventing the cascade of events that lead to cell lysis and inflammation, making Tesidolumab a valuable tool for research into complement-mediated diseases and therapeutic interventions.

Mezagitamab (TAK-079) is an IgG1λ monoclonal antibody targeting CD38. This antibody facilitates the depletion of tumor cells that express CD38 via mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is currently being investigated for its therapeutic potential in treating conditions such as relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP), demonstrating significant relevance in clinical research settings focused on hematologic malignancies and autoimmune disorders.

Fepixnebart is a humanized IgG4κ monoclonal antibody that specifically targets transforming growth factor-alpha (TGFA). This antibody is engineered for stability and minimal immune system engagement, making it an ideal tool for research into TGF-alpha's role in cell proliferation, differentiation, and its implications in oncological disorders.

Ontamalimab (SHP647) is a fully human IgG2 monoclonal antibody designed to specifically target mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This antibody is utilized in the investigation of Crohn's disease, providing a valuable tool for understanding the molecular interactions and pathways involved in this chronic inflammatory condition. Ontamalimab offers specificity and efficacy in research settings focused on gastrointestinal immunology and inflammatory disorders.

Ravagalimab (ABBV-323) functions as a potent CD40 antagonist with an EC50 value of 3.7 nM. This monoclonal antibody is primarily utilized in the research of Crohn's disease, offering a valuable tool for investigating the pathophysiology and potential therapeutic interventions targeting the CD40 pathway in this condition.

AK-001 is a fully human monoclonal antibody of the IgG1 subclass, specifically targeting Siglec-8. This antibody is designed for research applications, including the study of chronic rhinosinusitis with nasal polyps. For appropriate experimental controls, researchers should use Human IgG1 kappa as the isotype control when working with AK-001.

Pertuzumab is a humanized IgG1 monoclonal antibody designed to inhibit HER2 dimerization. This targeted mechanism of action makes it particularly effective in the treatment of metastatic HER2-positive breast cancer. Pertuzumab binds specifically to the HER2 receptor, blocking its ability to form dimers and activate downstream signaling pathways that promote tumor growth and survival. This agent is utilized primarily in research focused on understanding and treating HER2-positive breast cancer.

The Anti-IFNγ Antibody (B133.5) is a chimeric mouse IgG1 monoclonal antibody that specifically targets human interferon gamma (IFNγ). This antibody is ideal for use in various immunological assays, including ELISA, Western blot, and immunohistochemistry, to accurately detect and quantify IFNγ levels. For accurate experimental controls, it is recommended to use Mouse IgG1 kappa, Isotype Control.

Sipavibart is a human IgG1 λ2 monoclonal antibody targeting SARS-CoV-2. For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.

Varlilumab (CDX-1127) represents a pioneering human IgG1 monoclonal antibody targeting CD27. This therapeutic antibody exhibits potent anti-tumor activity, leveraging immune activation to selectively enhance the body's natural anti-cancer responses. Varlilumab is designed for specificity in binding to CD27, a critical molecule in the regulation of T-cell function and survival, making it a valuable tool in oncology research and therapeutic applications.

Lanadelumab (SHP643) is a human IgG1 monoclonal antibody specifically targeting plasma kallikrein (pKal), exhibiting a potent inhibitory constant (Ki) of 0.12 nM. This antibody is capable of inhibiting both free and high molecular weight kininogen (HMWK)-bound forms of pKal. Lanadelumab is primarily utilized in research focused on hereditary angioedema, offering significant potential for elucidating the pathophysiology and therapeutic targeting of this condition.

Oxelumab (R 4930) is a human monoclonal antibody specifically targeting the OX40 ligand (OX40L). This antibody is utilized primarily in the study of asthma, offering a precise tool for investigating the role of OX40L in immune modulation and inflammatory responses associated with this respiratory condition.

Isuventatug is a monoclonal antibody engineered to specifically bind to human MHC class I chain-related molecules A and B (MICA and MICB). By targeting these molecules, Isuventatug modulates the interactions between immune cells and tumor cells, thereby exerting antitumor effects. This antibody is particularly valuable in the study of cancer immunotherapy, providing a promising tool for researchers exploring innovative treatments in oncology.

Vilastobart is a human IgG1 κ monoclonal antibody targeting CTLA-4. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Baloramotide is a recombinant protein consisting of 182 amino acids derived from the NY-ESO-1 antigen. This biologic is designed to enhance the immune system's response to tumor cells by promoting the recognition and attack of cancerous tissues expressing the NY-ESO-1 epitope. It is utilized primarily in research focused on cancer immunotherapy and the development of vaccine strategies against NY-ESO-1 expressing tumors.

Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody designed to selectively inhibit activin A. This specificity makes it an ideal tool for investigating fibrodysplasia ossificans progressiva (FOP), providing valuable insights into the pathophysiology of this rare and debilitating condition. Garetosmab's targeted action on activin A opens avenues for exploring therapeutic interventions in FOP research.

Tacatuzumab is a human IgG1 κ monoclonal antibody targeting alpha-fetoprotein (AFP). For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody designed for selective binding to 4-1BB/CD137, a costimulatory receptor involved in the regulation of immune cell activation and survival. This antibody has potential applications in oncology research, particularly in the study of follicular and other CD20+ non-Hodgkin lymphomas, where it may enhance antitumor immune responses.

Sutimlimab is a pioneering inhibitor of complement protein component 1, subcomponent s (C1s), representing the first in its class. This therapeutic targets C1s, a serine protease essential for the cleavage of complement components C4 and C2, which are critical in the formation of C3 convertase. Sutimlimab is primarily utilized in research focused on cold agglutinin disease, providing significant insights into the pathophysiological mechanisms and potential therapeutic interventions for this condition.

AB-25E9 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-15, also known as CD33L3. This antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. AB-25E9 is designed for use in various immunological assays to study the role of Siglec-15 in immune regulation and its potential implications in therapeutic interventions.

ASK 8007 is a monoclonal antibody designed to target and neutralize osteopontin. This antibody is specifically engineered for high specificity and affinity to osteopontin, making it an ideal tool for research focused on the role of osteopontin in various biological processes and diseases, such as inflammation, cancer progression, and tissue remodeling. ASK 8007 is suitable for a range of applications including Western blot, immunohistochemistry, and ELISA.

Bremzalerbart is a human IgG4 monoclonal antibody that specifically targets BETVIA, identified as the primary allergen Bet v 1-A from birch pollen. This antibody is designed for the precise detection and neutralization of Bet v 1-A, making it highly relevant for research into allergic responses and potential therapeutic interventions for birch pollen allergies.

Temtokibart is a humanized IgG1λ2 monoclonal antibody that specifically targets the IL22RA1 receptor. This antibody is uniquely expressed by cells deficient in the glutamine synthetase gene, making it an essential tool for research focused on signaling pathways involving the IL-22 receptor. Temtokibart is ideal for studies investigating the role of IL22RA1 in various biological processes and diseases.

DEDN6526A (RG-7636) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the endothelin B receptor (ETBR). This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This specificity and configuration make DEDN6526A (RG-7636) ideal for research focused on the physiological and pathological roles of ETBR in various biological systems.

Caplacizumab (ALX-0681) is a humanized nanobody targeting the von Willebrand factor (vWF), designed to disrupt the interaction between vWF and platelet glycoprotein Ibα. By inhibiting this binding, Caplacizumab effectively prevents vWF-mediated platelet adhesion, thereby reducing the formation of microthrombi. This agent is particularly useful for research focused on thrombotic thrombocytopenic purpura (TTP), offering a valuable tool for investigating the mechanisms and potential treatments of this condition.

Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor (HGF), designed to inhibit HGF/MET signaling pathways. This antibody demonstrates potent anti-tumor activity and is primarily utilized in the study of castration-resistant prostate cancer (CRPC) and other solid tumors. Rilotumumab offers a strategic tool for researchers investigating the role of HGF/MET interactions in cancer progression and therapeutic resistance.

Bebtelovimab is a humanized IgG1-λ2 monoclonal antibody specifically designed to target SARS-CoV-2, the virus responsible for COVID-19. This antibody demonstrates potent neutralizing activity against various SARS-CoV-2 variants, providing mild-to-moderate efficacy in inhibiting the progression of COVID-19. Bebtelovimab is engineered for precise binding to the spike protein of the virus, disrupting its ability to infect host cells. This makes it a valuable tool for research into viral pathogenesis and the development of therapeutic strategies against COVID-19.